Bruker UHR-QTOF-MS maXis II™ ÀÇ Biopharma ºÐ¼® : ´ÜÀÏŬ·ÐÇ×ü ºÐ¼® ¹× °³¹ßÀ» ½±°í ºü¸£°Ô!
Introduction
maXis II: Unmatched Performance
°Å´ë ºÐÀÚ (> 25 kDa) ¹× °ü·Ã º¯ÀÌü¿¡ ´ëÇÑ ´ÜÀÏ µ¿À§ ¿ø¼Ò Áú·®À» °áÁ¤ÇÏ´Â °ÍÀº ÃÊ±â ´Ü°è °³¹ß Áß ´ÜÀÏ Å¬·Ð Ç×ü ¹ß´Þ¼º Æò°¡¿¡ ÇʼöÀûÀÌ´Ù.
maXis II UHR-QTOF Áú·® ºÐ¼®±â´Â SNAP-II deconvolution ¾Ë°í¸®Áò°ú ÇÔ²² °Å´ë ´Ü¹éÁú ¹× Ç×ü ÀÌÁú¼ºÀÇ ½Å¼ÓÇÑ ÇÁ·ÎÆÄÀϸµÀ» À§ÇÑ ÃÖÀûÈµÈ ÀåºñÀÌ´Ù.
Feature & Application
Fig.1 Sub-unit characterization (e.g. de-amidation) using the power of True Isotopic Pattern (TIP) raw data
maXis II´Â °æ¼â (LC)ÀÇ Å» ¾Æ¹Ìµå È¿Í °°Àº º¯ÇüÀÇ ½Å¼ÓÇÑ °áÁ¤À» °¡´ÉÇÏ°Ô ÇÏ´Â True Isotopic Pattern (TIP) ¿ø½Ã µ¥ÀÌÅ͸¦ ȹµæÇϸç, SNAP-II ¾Ë°í¸®Áò°ú °áÇÕµÈ ÀÌ ¹Ì¼¼ÇÑ º¯ÇüÀº ÇÏÀ§ ´ÜÀ§ ¼öÁØÀÇ Æ¯Â¡À» °áÁ¤ÁöÀ» ¼ö ÀÖ´Ù.
The ‘de facto’ standard for biologics
Fig.2 MaxEnt deconvolution spectrum measured in blue. Simulated mass spectrum in black.
maXis II UHR-QTOF´Â »ý¹°ÇÐÀû Á¦Á¦ ºÐ¼®¿¡ ÀÖ¾î ±Û¶óÀÌÄÀÇ Ã¶ÀúÇÑ Æ¯¼º ±Ô¸íÀ» ÅëÇØ Ç×üÀÇ PK Ư¼ºÀ» ÀÌÇØÇÏ°í ¿¹ÃøÇÑ´Ù. Á¤È®ÇÏ°Ô deamidationÀ» °áÁ¤ÇÏ°í ½Å¼ÓÇÑ ¾à¹° ´ë Ç×ü ºñ(Drug-Antibody Ratio, DAR), Àϰý 󸮿¡ ´ëÇÑ º¯µ¿¼º ¸ð´ÏÅ͸µÀ» ÅëÇØ clinical pharma ºÐ¾ß¿¡ ÀÖ¾î ½Å¼ÓÇÑ ¼Óµµ¸¦ Á¦°øÇÑ´Ù.
¶ÇÇÑ maXis II UHR-QTOF´Â electron transfer dissociation (ETD)´Â ¹°·Ð °íÀ¯ÀÇ MS ÀÀ¿ë ÇÁ·Î±×·¥À» À§ÇÑ °íÁú·®¿É¼Ç(HMO)¸¦ °®Ãß°í ÀÖ´Ù.
Superior Glycan Profiling Performance
±Û¶óÀÌÄÚ½ÇÈ(glycosylation)Àº ¸¹Àº »ý¹° ÀǾàǰÀÇ Áß¿äÇÑ ¼Ó¼ºÀÌ µÈ´Ù. ±Û¶óÀÌÄÚ½ÇÈ ÇÁ·ÎÆÄÀϸµÀÇ ÀÛÀº º¯È°¡ ¾ÈÁ¤¼º, À¯È¿¼º¿¡ Áß¿äÇÑ ¿µÇâÀ» ¹ÌÄ¥ ¼ö Àֱ⠶§¹®ÀÌ´Ù. ±Û¶óÀÌÄÚ½ÇÈ ¼öÁØÀ» È®ÀÎ, ¸ð´ÏÅ͸µ ¹× Á¦¾îÇÏ´Â °ÍÀÌ ¼º°øÀûÀÎ »ý¹°ÇÐÀû ¾àÁ¦ °³¹ßÀÇ ÇÙ½ÉÀ̸ç, À̸¦ maXis II UHR-QTOF°¡ ½Å·Ú¼º ÀÖ°Ô Ã³¸®ÇÏ°Ô ÇØÁØ´Ù.
Fig.3 Intact ¼öÁØÀÇ ÇÁ·ÎÆÄÀϸµÀº ÀϹÝÀûÀ¸·Î 10-20ppmÀÇ Á¤È®µµÀÌ´Ù.
ºÐÇØ µ¿À§ ¿ø¼Ò (<50 kDa)´Â 1 ppm ÀÌÇÏ·Î ¶³¾î´Âµ¥ maXis II UHR-QTOF´Â ´ëÇü ´Ü¹éÁú ¹× ±Û¶óÀÌÄÚ ÇüŸ¦ À§ÇÑ Å¸ÀÇ ÃßÁ¾À» ºÒÇãÇÏ´Â ´ÙÀ̳»¹Í ·¹ÀÎÁö¸¦ °¡Áö°í ÀÖ¾î ´Ù¾çÇÑ ¹üÀ§ÀÇ ºÐ¼®ÀÌ °¡´ÉÇÏ´Ù.
Increased Confidence in Released Glycan Analysis
2AB ¹× RapiFluor¢ç Ç¥ÁöµÈ ±Û¶óÀÌÄ (´ëºÎºÐÀÇ IgG ¾ÆÇü°ú 15°³ ÀÌ»óÀÇ ¼¼Æ÷ÁÖ¸¦ Æ÷ÇÔÇÑ 25°³ÀÇ ´ç ´Ü¹éÁú)ÀÇ Á¤È®ÇÑ Áú·® ¹× MS/MS ½ºÆåÆ®·³À» Æ÷ÇÔÇÏ´Â °æÇèÀû ½ºÆåÆ®·³ ¶óÀ̺귯¸®¸¦ Á¦°øÇϸç, ÀÌ´Â µ¥ÀÌÅÍ Ã³¸®. ´ÜÆí °µµ ¹× coeluting glycansÀÇ Á¤·®À» ¹ÙÅÁÀ¸·Î ½ºÄھ ÇÏ¿© ÃÖ¼ÒÈµÈ »ç¿ëÀÚ °³ÀÔÀ¸·Î MS ¹× Çü±¤ ±â¹Ý µ¥ÀÌÅ͸¦ Æ÷ÇÔÇÑ º¸°í¼¸¦ »ý¼ºÇØÁÖ°í ±ÔÁ¦ ¹× ±Ô°ÝÈµÈ ºÐ¼®¿¡ Àû¿ë ÇÒ ¼ö ÀÖ´Ù.
Fig.4 GlycoFiler º¸°í¼ ÃßÃâ °á°ú : IgG1 ¹× EGFR¿¡ ´ëÇÑ Çü±¤ Å©·Î¸¶Åä±×·¥Àº ÁÖ¿ä È®ÀÎµÈ ±¸Á¶¿¡ ÇÒ´çµÈ ±Û¶óÀÌÄÀ» ¹æÃâÇÑ´Ù.
Rapidly Characterize Drug-Antibody Conjugates under GLP
maXis II´Â ¼Õ»óµÇÁö ¾ÊÀº(intact) Ç×ü¿¡¼ Á÷Á¢ ¹Ì¼¼ ÀÌÁú¼ºÀ» ½±°Ô °ËÃâÇϰí Á¤·®È ÇϹǷΠHPLC ¸Þ¼Òµå°¡ È®¸³µÇ´Â °ÍÀ» ±â´Ù¸± ÇÊ¿ä ¾øÀÌ ¾à¹° ºÐÆ÷ ¹× Æò±Õ ¾à¹° ºÎÇÏ (DAR) ºÐ¼®À» ½Å¼ÓÇÏ°Ô °³¹ßÇÒ ¼ö ÀÖ´Â ¿Ïº®ÇÑ Ç÷§ÆûÀÌ´Ù. Á÷±³ ¹æ¹ý ¹× °ß°í¼º°úÀÇ ºñ±³´Â GLP ÀÛ¾÷¿¡ ´ëÇØ ÀÌ·¯ÇÑ ¹æ¹ýÀ» °ËÁõ ÇÒ ¼ö ÀÖ°Ô ÇÕ´Ï´Ù.
BioPharma Compass: Designed in collaboration with the pharmaceutical industry
LC-UV, MS ¹× MS / MS µ¥ÀÌÅ͸¦ ¿Ïº®ÇÏ°Ô ÅëÇÕÇÏ¿© ÃÖ°íÀÇ µ¿Àû ¹üÀ§·Î ¿À·ù º¸»ó Á¤·®À» Á¦°øÇÑ´Ù.¼Õ»óµÇÁö ¾ÊÀº ´Ü¹éÁú ¹× ÇÏÀ§ ´ÜÀ§ ºÐ¼® ¶Ç´Â ÆéŸÀÌµå ½ºÅ©¸®´× ¹× Á¤·® ¿öÅ© Ç÷οì¿Í °°Àº ±â´ÉÀ» Æ÷ÇÔÇÏ´Â ÇϳªÀÇ ¼ÒÇÁÆ®¿þ¾î Ç÷§ÆûÀ» Á¦°øÇÑ´Ù.